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Abstract
Glioblastoma multiforme is the most deadly primary brain tumor. Current ther-
apies have not demonstrated improved outcomes for patients; generally the median 
life expectancy is 8–15 months. Due to brain tumor cells dependence on glucose as a 
sole energy source, there is potential to target treatments towards glucose metabo-
lism. The ketogenic diet (KD) is a high fat, low carbohydrate diet that has proven 
successful in the animal model. However, human studies are limited and there 
currently is not enough research to conclude the KD is an effective therapy. A few 
aspects need to be addressed for inclusion in protocols of future studies: (1) when 
to initiate the KD during treatment; (2) how much carbohydrate per day to provide 
to patients; (3) how to ensure patient compliance to diet; (4) the optimum duration 
of the diet; (5) how to mitigating patient weight loss. In addition, the registered 
dietitian nutritionist (RD or RDN) is a vital, and underutilized, member of the 
health care team. The inclusion of a RD to future KD protocol, as well as oncology 
practices, can enhance patient outcomes and help future patients overcome barriers 
when adhering to the KD.
Keywords: nutrition, ketogenic diet, glioblastoma multiforme, registered dietitian 
nutritionist, brain cancer
1. Introduction
In 2013, it was estimated that there were 23,130 cases of primary brain cancer 
in the United States and 14,080 deaths from the disease [1]. One type of tumor is 
glioblastoma multiforme (GBM), which is the most deadly primary brain tumor in 
children and adults [2]. Most cases of GBM occur in patients over the age of 50 years 
old [3]. Current median life expectancy for these patients is 8–15 months; 1 year 
survival is 34.6% and 5 year survival is less than 5% [1, 3]. Standard treatment is 
typically palliative in nature and includes surgery (maximal tumor resection), radia-
tion, as well as chemotherapy [2, 3]. While there are new therapies, which include 
gene therapy, immune modulating therapy and anti-angiogenic therapy, these have 
not demonstrated improved outcomes for this disease [4]. Overall, the current aims 
of therapies are to increase life expectancy and enhance quality of life [3].
Patients with cancer often have a “wide range of nutrition related problems” [5]. 
These nutritional issues may occur anywhere along the digestive tract-from 
 salivary dysfunctions to changes in stooling and often involve weight loss [5]. Other 
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patients may be at higher risks of developing morbidities such as “diabetes, adi-
positas, hyperlipidemia or cardiovascular disease” related to cancer therapies [5]. 
Patients with head and neck cancers have a high risk of mortality (50%) and many 
of these patients suffer from malnutrition [6]. This is often a result of the malig-
nancy and may be attributed to loss of appetite, difficulties eating, weight loss as 
well as fatigue [6]. Malnutrition is an issue as it may cause setbacks in healing, such 
as weakened immune system, longer treatment times and increased complications 
along with the cancer [6].
When it comes to medical nutrition therapy (MNT), cancer patients are often 
“under-recognized and undertreated” as a patient population [5]. Data constantly 
demonstrates that patients with cancer that do not receive MNT have decreased 
likelihood of responding to therapies and success may be lower [5]. A registered 
dietitian nutritionist (RD or RDN) is trained to deliver nutrition facts as well as 
scientifically based nutrition education and counseling, while also considering 
educational levels and “psycho-oncological” influences [5]. Current nutrition 
recommendations correspond generally to patients with head and neck cancer, 
and there are no specific nutrition recommendations for patients with GBM. The 
ketogenic diet (KD) has shown promising results in the animal model for malignant 
brain tumors, but as of 2015, very few studies detail the treatment of primary brain 
tumors with the KD [1]. Currently, the data is limited whether the KD is effective 
for patients with GBM for improving outcomes and extending longevity. In addi-
tion, the question remains: should health professionals recommend the KD as a 
therapeutic treatment for patients with GBM?
2. Brain cell metabolism
The brain is a “metabolically active organ” that is almost completely dependent 
on glucose as its exclusive energy source [7]. Without the ability to locally store 
glucose, the brain relies on tight homeostasis of blood glucose to ensure adequate 
energy supplies [7]. Blood glucose concentrations are considered normal between 
70 and 144 mg/dL, while any concentration over 200 mg/dL is considered hypergly-
cemic [7].
For patients with GBM, blood glucose concentrations have been found to average 
459 mg/dL [7]. In part, this may be due to high dose of glucocorticoids to help 
with peritumor associated edema [8, 9]. Glucocorticoids usage results in impaired 
glucose transport and high plasma glucose [8]. In addition, glucose metabolism is 
higher in environments with poor blood supply, such as acidic and hypoxemic envi-
ronments [7]. This may be attributed to the Warburg effect. This effect is part of the 
aberrations observed in cancer cell metabolism; it involves a switch from  oxygen 
dependent oxidative phosphorylation to “glucose intensive” anaerobic glycolysis 
for ATP production [7]. This results in the production of essential proteins, lipids 
and nucleic acids required for cell growth under hypoxic conditions [7]. Tumors 
in microenvironments are negative indictors of “therapeutic response” and overall 
survival [7]. Previous work has demonstrated that cancer cells have enhanced 
aptitude to defy damage from radiation when in hyperglycemic environments [10]. 
Unfortunately, due to high mortality rate, and decreased likelihood of patients 
developing diabetes in the long term, hyperglycemia is not managed by intensive 
therapies; rather, the goal is to avoid acute complications [8]. However, previous 
studies have demonstrated that higher amounts of glucose in the brains of cancer 
patients is correlated to a shorter survival [7, 8]. Other reports have demonstrated 
that the higher the glucose levels, the faster the tumor growth [9]. Glioma cells have 
previously been shown to display a “threefold increase” in the rate of glycolysis 
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compared to normal astrocytes and when glucose is removed; this leads to apoptosis 
in tumor cells, compared to normal cells [11].
When the brain has decreased access to glucose, it is able to metabolize ketone 
bodies (acetoacetate and β-hydroxybutyrate) for energy [9]. This occurs as the liver 
transforms fat into ketone bodies and fatty acids. The ketone bodies then circulate 
to the brain and substitute glucose as the brain’s energy source [4]. The benefit is 
that as brain tumor cells are completely dependent on glucose to perform glycolysis, 
they are unable to metabolize ketones. The latter is due to impaired mitochondria 
[2]. Another benefit is that ketones may be toxic to some tumor cells by decreasing 
free radicles from oxygen and improving metabolism in healthy cells [9]. Therefore, 
focusing anti-tumor treatments on glucose metabolism may be beneficial for GBM 
patients’ outcomes [2].
2.1 The ketogenic diet
The ketogenic diet (KD) was established in the 1920s and consists of a high 
fat content while providing a low carbohydrate content [2, 10]. It is best executed 
under medical supervision; it has been effective for treating children with epilepsy 
and may be successful in neurodegenerative diseases such as Alzheimer’s and 
Parkinson’s [2, 12]. The diet is successful as it mimics the fasting state by increasing 
the level of ketones circulating in the blood, while decreasing circulating glucose; 
this diet also avoids malnutrition in patients [2, 10]. The KD typically consists of 
90% fat, with the remaining 10% contributed by both protein and carbohydrate 
[13]. Protein is indispensable in the diet, but too much protein can result in the 
transformation to glucose via gluconeogenesis and act metabolically as a carbo-
hydrate [13]. It has previously been demonstrated that extremely malnourished 
oncology patients that were given a diet consisting of 44 kcal/kg, where medium 
chain triglycerides provided 70% of the macronutrient content, had no significant 
changes in nitrogen balance or protein synthesis [13].
Using the KD as a therapeutic approach for malignant brain cancer rests on 
the assumption that brain tumors do not have the necessary enzymes to oxidize 
ketones, and are based on successful rodent studies [4]. However, a recent study 
contradicted previous findings and reported that rodent brain tumors were able to 
metabolically change and the “up regulation of the ketone body monocarboxylate 
transporter,” which “facilitated the update and oxidation of ketone bodies in the 
gliomas” [4]. To date, there are very few human studies and most of them have 
small sample sizes [4]. Using the KD as the sole treatment or part of the treatment 
may be effective against GBM, and has been suggested and discussed in previous 
literature [3, 9, 14].
Another idea worth noting is that the treatment of GBM with the KD may be 
enhanced by a calorie restriction; this idea has been shown to prevent tumor prog-
ress in a range of models [15]. Schwartz et al. provided a calorie restriction after 
calculating energy needs based on ideal body weight, then providing 20–25 kcals/kg 
with a 20% restriction in kcals per day [1]. A calorie restriction typically provides a 
20–40% reduction in daily calories. During calorie restriction, serum levels of glu-
cose and insulin decrease while fat breakdown increases. This eventually activates 
peroxisome proliferator-activated receptor-α (PPAR-α), which hinders glycolysis 
and fatty acids production. PPAR-α also stimulates transcription of enzymes that 
promote ketogenesis and fatty acid oxidation in the mitochondria and peroxisome 
[13]. For the tumor cells, which lack the enzymes needed to metabolize ketones, 
energy in the form of adenosine triphosphate (ATP) can no longer be produced via 
glycolysis; the cells also lack the ability to compensate via oxidative phosphoryla-
tion, which deprives the cell of ATP and means for growth [13]. A calorie restriction 
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may be a beneficial aspect along with the KD, but is not consistently explored in KD 
studies. A few concerns should be addressed when considering the KD as a thera-
peutic treatment for patients with GBM: carbohydrate content of diet; compliance 
to diet; when to initiate the diet; duration of diet; quality of life, and involving a RD 
with the treatment protocol to improve outcomes.
2.2 Exploring best practices
While the KD typically provides 90% fat, the amount of carbohydrate permit-
ted during treatment tends to vary with each study [13]. In the human studies 
investigated, the carbohydrate content ranged from 10 grams (g) per day, up to 
70 g per day [2, 16]. Previous studies using the animal model have demonstrated 
that by restricting carbohydrates to <50 g/day, ketone levels ≥1 millimoles per 
liter (mmol/L) enhances the expression of monocarboxylic acid transporters in 
the brain; this results in the movement of ketones through the blood brain bar-
rier [13]. An issue with very restrictive dietary carbohydrate is that patients with 
malignant tumors have been documented to have higher rates of gluconeogenesis, 
which decreases the body’s stores of lean mass and hurts the patient [16]. Therefore, 
cancer patients may benefit from slightly more carbohydrate, and not risk leaving 
ketosis [16]. In addition, more carbohydrate options increases the types of food 
that can be eaten, which helps with compliance [16]. Best practice may be to allow 
patients to eat around 50 g of carbohydrate per day, which may improve adherence 
to the prescribed diet and improve treatment outcomes.
Compliance to the KD is an issue as it requires a lifestyle change, which may 
be difficult for some patients [16]. It is not uncommon for studies to report that 
some participants had low compliance [4, 16]. However, a few participants found 
the KD was tolerable: the diet was rated as good by seven patients, moderate by 
three patients and poor by only one patient [16] and was reported to be “relatively 
well tolerated” [15]. One patient was reported to strictly adhere to the KD and a 
calorie restricted diet for 56 days [2]. For patients following the KD, it is important 
for strict adherence to the diet. For those with strict compliance to the KD, it was 
reported there was a partial response to treatment, and ketone bodies were found 
in the normal appearing white matter 8 months after starting the diet; although, 
this response was attributed to bevacizumab therapy and not the KD [4]. However, 
there may be other barriers that exist that hinder patients from strictly adhering to 
the diet. To help mitigate these barriers, the addition of a RD to the treatment team 
would be best practice; this will be discussed later in the chapter.
Having patients test their own ketone and glucose levels may help them to com-
ply with the diet, as they can see if their levels are in goal range. The goal for GBM 
therapy is to have blood glucose ranges between 55 and 65 milligram per deciliter 
(mg/dL) for maximum therapeutic implications [2]. To measure compliance to the 
KD, ketones are measured via urine analysis; however, there is evidence to show 
that urine concentrations are not reflective of the concentrations of ketones avail-
able to the brain for consumption [4]. Artzi et al. reported only three incidences 
where ketones were found in the brain using magnetic resonance spectroscopy 
(MRS): two times in the normal appearing white matter, at 4 and 25 months after 
starting KD, and one in the tumor area 13 months after starting KD; it was noted 
that participant compliance to the KD was low [4]. Compliance to the KD was 
measured either by urine analysis or by blood analysis. The goal for urine ketones 
was set >2, while blood ketone goals were between 3 and 8 mmol/L [1, 4]. It was 
reported that 92% of patients that tested urine ketones 2–3 times per week achieved 
ketosis at least one during the study [15]. Schwartz et al. went further and also 
had their participants test their blood glucose at least two times per day. Goals for 
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blood glucose were between 50 and 70 mg/dL, which is a suggested best practice for 
maximum therapeutic effect [1]. A benefit to testing ketones via the blood is that 
the patient can also test blood glucose and have measureable results. While the goal 
for blood glucose is 50–70 mg/dL, it is important that patients keep track of blood 
glucose to avoid hypoglycemic events, which is defined as blood glucose <45 mg/dL 
[2]. Hypoglycemia is a concern because if it goes untreated it can lead to coma and 
death [17]. However, it has been reported that while following the KD, there was no 
issue with hypoglycemic events, and that patients that had elevated blood glucose 
prior to the study, ended up with normal levels after starting the KD [2, 16]. There 
is valid concern that ketosis, defined by urine or blood concentrations, may not be 
indicative of the brain and tumor usage of ketones. However, MRS may not be a tool 
available for all patients and providers. Best practice would be to have patients test 
blood glucose and ketones 2–3 times per day to help with measurable goals, help 
encourage compliance and to avoid any hypoglycemic events.
While the KD has been promising in the mouse model, the studies in human 
clinical trials have yet to clearly demonstrate that the KD is effective as a sole inter-
vention. Part of the issue is that the KD has not been consistently used an isolated 
therapy and many of the studies use KD concomitantly with other treatments; 
therefore, the studies have not able to conclude if the KD was an effective therapy 
[1, 2, 4, 16]. However, the KD may be most effective when used in combination with 
chemotherapy. Rieger et al. found that patients that received the KD and received 
bevacizumab had a median progression free survival of 20.1 weeks while patients 
receiving bevacizumab and not on the KD had a median progression free survival of 
16.1 weeks [15].
The duration of the KD ranged greatly amongst the studies, and there does not 
appear to be a pattern for best practice. However, it has previously been reported 
that effects of the KD cannot be ascertained until after 8 weeks on the diet [16]. As 
mentioned previously, a case study reported on a patient following the KD and a 
calorie restriction for 56 days, then discontinued the KD and followed a low calorie 
diet for 5 months and was found to be disease free at that follow up [2]. Artzi et al. 
had dietary components that lasted from 2 months up to 31 months, although not 
all patients were able to follow the KD strictly [4]. Meanwhile, Reiger et al. had a 
median duration of 36 days for diet adherence and reported that patients followed 
the diet for 6.8 days out of the week. Schwartz et al. reported two participants fol-
lowed the KD for 12 weeks, but there was no benefit to stopping tumor growth [1]. 
Meanwhile, there was evidence that the KD could be effective for longer “progres-
sion free survival;” in patients with stable ketosis, the median overall survival was 
32 weeks, with a range from 6 to 86+ weeks [15]. Current recommendations state 
that dietary interventions should be started before cancer treatments then continue 
along with and after treatments; it also may be more successful of an intervention if 
a registered dietitian is an active part of the treatment team [18].
Nutrition status and quality of life have a positive relationship and both are 
associated with survival [10, 19]. While most patients with GBM have a short life 
expectancy, it is important that their quality of life is maximized, and the quality 
of their diet is an important factor. Food is one of the few aspects of health that 
both patients and care givers continue to have control over, and is both a “mental 
and social act” that has many external influences [5]. Schmidt et al. investigated 
the quality of life for patients with different types of cancer on the KD. Quality 
of life was initially low for participants due to stage of tumor progression, but the 
KD was found to increase their quality of life over time. Symptoms of fatigue, pain 
and dyspnea amplified over time, but emotional function and insomnia improved. 
Previous side effects reported on the KD have included vomiting, fatigue, hunger 
and constipation; however, the study reported no incidence of hunger, meanwhile 
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nausea and vomiting were reported as infrequent [16]. In addition, the KD has been 
found to have no adverse neurological or physiological impacts for patients [2].
Another aspect of quality of life is weight loss. Ten to eighty-three percent of 
patients with cancer may have unwanted weight loss [5]. The KD in theory should 
mimic the benefits of long term fasting, while avoiding weight loss in the “oncologi-
cal setting” [10]. The KD is intended to meet the energy and nutrition requirements 
of oncology patients while also stimulating lean body mass recovery [13]. From a 
nutrition perspective, unintentional weight loss is defined as ≥5% in 1 month or 
≥10% in 6 months [18]. In the few studies that investigate the KD, most reported 
that participants lost weight [1, 2, 15, 16]. Zuccoli et al. reported on a patient that 
received the KD along with a calorie restriction and after 20 days had experienced a 
13.4 pound (9.5%) weight loss, which is nutritionally significant based on malnutri-
tion criteria [2, 20]. It is to be noted that this patient was on a calorie restriction of 
600 calories per day [2]. Meanwhile, Rieger et al. reported a statistically significant 
weight loss of 2.2% overall for patients on the KD [15]. While the KD, especially 
if paired with a calorie restriction, may cause weight loss, one of the goals during 
cancer treatment is preventing malnutrition. Significant weight loss is one of the 
criteria used to diagnose malnutrition. Malnutrition has been found to be the lead-
ing reason for interrupted treatments [6].
Overall, the KD appears relatively safe for patients with GBM, and may help 
increase longevity, although excessive weight loss may be a concern. It is important 
that patients following the KD have a balance of food choices to increase quality 
of life and mitigate weight loss while also adhering to the KD for best treatment 
outcomes.
2.3 Role of registered dietitian in cancer treatment
It is essential for patients with head and neck cancers to follow nutrition advice 
for best “treatment and health outcomes” [6]. Patients that participated in a nutri-
tion intervention during treatment were able to “maintain or improve nutritional 
status” as well as improving the rate of treatments completion, decreasing hospital 
visits, length of hospital stays and decreasing the amount of weight lost during 
treatment [6]. Unfortunately, patients with head and neck cancer are not always 
compliant with dietary advice, especially if dietary is not considered an essential 
part of the treatment by patients [6]. It has previously been reported that more 
participants received nutrition counseling after treatment (60.7%) compared to 
during cancer treatment (47.4%) [5].
When considering diet therapy in combination with anti-tumor treatments, 
it would be best practice to consult a registered dietitian. A registered dietitian 
nutritionist (RD or RDN) is a food and nutrition expert with a bachelor and/or 
master degree from an accredited university, and has taken coursework that has been 
approved by the Accreditation Council for Education in Nutrition and Dietetics. 
In addition, the RD has completed a 1200 hour supervised practice with rotation 
concentrations in clinical, community and food service management, and passed a 
national credentialing exam. RDs have to take continuing education credits, regarding 
up-to-date food and nutrition information, to maintain RD credentials. RDs also have 
the option to become certified in specific areas of practice; one such area is oncology 
[21]. RDs are trained to do assessments and give detailed nutrition educations. As 
part of the assessment, the RD assesses current weight and discusses weight history, 
discusses current nutrition symptoms, assesses diet history, and calculates protein 
and energy needs [22]. RDs use the nutrition care process, which is an internationally 
validated and accepted tool, which makes nutrition care more visible amongst the 
health profession and ensures access of information to qualified professionals [5].
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The RD is an integral part of the health care team, and may be an underutilized 
resource. Maschke et al. found that cancer patients were more likely to receive 
nutrition advice from a dietitian if they were between ages 45–70 years old, and 
those patients between ages 27–45 years old received nutrition information from 
the internet, nurse or doctor. It would have been beneficial for more patients to see 
a dietitian as the most often reported questions was regarding a “healthy diet” as 
well as issues with fatigue and weakness [5]. Kiss et al. found that when the dietitian 
clinic was located separately from the oncology clinic, the RD was not included as 
part of the multidisciplinary team and patients did not attend the dietitians’ clinic. 
When the RD team was moved to be a part of the oncology team, it was found to 
improve communication amongst team members, resulting in the ability to quickly 
identify nutrition complications and reduce hospital admissions [22].
In regards to the studies administering the KD to patients, a RD was mentioned 
in a few studies as part of the protocol. Benefits of adding the RD as a part of the 
study protocol team is the ability to check in on patients more often, either via the 
phone or in the clinic, answer questions and refer patients to the doctor if there are 
medical treatment issues that arise. This can help take part of the burden off of the 
doctors [1]. In addition, it has been reported that when patients visited with a RD 
regularly, the percent of patients admitted to the hospital for nutrition related issues 
decreased from 12 to 4.5% and that hospital days decreased from 199 to 62 days 
[22]. The RD has the expertise and the experience to calculate energy and protein 
needs as well as diet plans to fit patient’s individual needs, which has some benefit 
[4]. To best highlight this, it is best to discuss the studies that do not involve a 
RD. For the two studies that did not provide patients with a RD, the study provided 
patients with instructions or a diet manual with a list of foods, the nutrition con-
tents of foods, recipes and rules to follow when on the KD. Patients were left to their 
own devices to prepare meals and only one of the studies provided a daily menu 
[15, 16]. This could be one of the barriers that prevented patients from strictly 
adhering to the KD. Previous findings have shown that individualized diet counsel-
ing based on patients’ normal food preferences, along with head and neck cancer 
treatments, is a very successful way to improve patients’ nutrition status, nutrition 
intake and quality of life [19]. Maschke et al. reported that over half of their study 
respondents wanted nutrition information, which suggested there is a need for 
providing consistent and evidenced based MNT. In addition, they suggested that 
there is the potential for a strong partnership between RDs and oncologists to meet 
the “informational needs” of patients [5]. The majority of the cancer patients that 
followed a special diet reported they adhered to it after receiving education from a 
registered dietitian [5].
3. Conclusion
GBM is a deadly primary brain tumor and patients with this diagnosis have 
a limited life expectancy. The ketogenic diet has shown promising results in the 
animal model and in theory should work to target brain tumor cells’ glucose 
metabolism. However, it is difficult to draw conclusions on the effectiveness of 
the diet due to the limited number of studies, small sample sizes, and the inability 
to use the KD as an isolated therapy. More studies need to be performed before 
the KD can be recommended as a sole therapy for GBM, and using the KD as a 
therapy should occur only with direct medical supervision. Future research needs 
to include a standardized protocol for including KD in studies. Based on the cur-
rent literature, best practice would include: (1) initiate KD prior to chemotherapy 
and continue concomitantly with chemotherapy; (2) KD composed of 50 grams of 
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carbohydrate per day; (3) patients test blood levels of ketones and glucose daily for 
compliance and to prevent hypoglycemia; (4) continue the KD for at least 8 weeks; 
(5) minimize patient weight loss. In addition, it would be best practice to include 
a registered dietitian nutritionist with the protocol to improve patient outcomes, 
educate patients on the KD, monitor patient progress, calculate energy needs and 
help patients overcome potential barriers while following the KD.
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